Clinical Trial Protocol
Iranian Registry of Clinical Trials

07 Nov 2026

Comparative bioequivalence study of Celecoxib 200 mg Capsule of Dorsa Pharmaceutical Doroxib and Celebrex® of Pfizer

Protocol summary

Study aim
This study will be performed to compare the pharmacokinetics and invivo parameters of Celecoxib 200 mg formulation as a test product with Celebrex® tablet formulation as a reference product and to evaluate the biocompatibility of these two formulations.

Design
Non-blinded, randomized, crossover in vivo bioequivalence study in 24 healthy subjects under fasting conditions. Block randomization for a treatment sequence of Test/Reference or Reference/Test is used.

Settings and conduct
In each period, volunteers will receive a single dose of the treatment in the Noor Research and Development Institute (Tarasht, Tehran). 2 dosing periods will be separated by a 7-day washout period.

Participants/Inclusion and exclusion criteria
Healthy subjects (male) between 18–55 years of age and Body Mass Index (BMI) 18.5 - 30 (inclusive); Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, and laboratory evaluations; Subjects with normal vital signs; Known hypersensitivity to Aprepitant or its analogs; Smoking more than ten cigarettes per day and could not tolerate cigarette cessation during each clinical period.

Intervention groups
Intervention group (test): Celecoxib 200 mg capsule, produced by Dorsa Pharmaceutical Co. is the test product. In each period, 12 of 24 subjects will be given a single oral dose of this product. Intervention group (Reference): Celebrex® capsule, produced by Pfizer is the reference product. In each period, 12 of 24 subjects will be given a single oral dose of this product.

Main outcome variables
Peak Plasma Concentration

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20180620040164N106**
Registration date: **2026-05-10, 1405/02/20**
Registration timing: **prospective**

Last update: **2026-05-10, 1405/02/20**
Update count: **0**

Registration date
2026-05-10, 1405/02/20

Registrant information

Name
Behzad Montaha Sangari

Name of organization / entity
Noor research and educational institute (Tavan)

Country
Iran (Islamic Republic of)

Phone
+98 21 6600 7026

Email address
info@tavaninstitute.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2026-06-26, 1405/04/05

Expected recruitment end date
2026-07-03, 1405/04/12

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Comparative bioequivalence study of Celecoxib 200 mg Capsule of Dorsa Pharmaceutical Doroxib and Celebrex® of Pfizer

Public title
Bioequivalence study of Celecoxib 200 mg Capsule in 24 healthy subjects under fasting conditions

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:
Healthy subjects (male) between 18 – 55 years of age Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m2. Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations. Subjects with normal vital signs.

Exclusion criteria:
History of known sensitivity to the tested products Associated acute or chronic infections Systolic blood pressure less than 90 or more than 140 mm Hg and diastolic less than 50 or more than 90 mm Hg. Heart rate less than 50 or more than 100 beats per minute Smoking more than 10 cigarettes a day History of alcohol or drug abuse Loss of more than 500 ml of blood in less than 7 days

Age
From **18 years** old to **55 years** old

Gender
Both

Phase
Bioequivalence

Groups that have been masked
No information

Sample size
Target sample size: **24**

Randomization (investigator's opinion)
Randomized

Randomization description
The randomization schedule will be generated with https://www.sealedenvelope.com/simple-randomiser/v1/lists. A 2*2 block randomization list is created. We have 12 blocks and within each two volunteer numbers (allocated after screening) for all 24 volunteers. According to this list, a treatment sequence of Test/Reference or Reference/Test will be given to each volunteer.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Crossover

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ethics committee of Shahid Beheshti University of Medical Sciences

Street address
Niayesh Highway, Valiasr Ave, Tehran, Iran

City
Tehran

Province
Tehran

Postal code
1996835113

Approval date
2026-05-04, 1405/02/14

Ethics committee reference number
IR.SBMU.PHARMACY.REC.1405.064

Health conditions studied

1

Description of health condition studied
Pain

ICD-10 code
R52

ICD-10 code description
Pain, unspecified

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax)

Timepoint
14 blood samples will be withdrawn pre-dose and at 0/5، 1، 1/5، 2، 2/5، 3، 4، 6، 8 ،10، 12، 24، 48 hours after intervention.

Method of measurement
using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)

Timepoint
14 blood samples will be withdrawn pre-dose and at 0/5، 1، 1/5، 2، 2/5، 3، 4، 6، 8 ،10، 12، 24، 48 hours after intervention.

Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA)

Intervention groups

1

Description
Intervention group (test): Celecoxib 200 mg capsule, produced by Dorsa Pharmaceutical Co. is the test product. In each period, 12 of 24 subjects will be given a single oral dose of this product.
Category
Treatment - Drugs

2

Description
Intervention group (Reference): Celebrex® capsule, produced by Pfizer is the reference product. In each period, 12 of 24 subjects will be given a single oral dose of this product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Noor Research & Development Institute (Tavan)
Full name of responsible person
Behzad Montaha Sangari
Street address
Sharif Innovation Station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht.
City
Tehran
Province
Tehran
Postal code
1459926609
Phone
+98 21 6600 4027
Email
info@tavaninstitute.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Dorsa Pharmaceutical Co.
Full name of responsible person
Amir Esmael Saghafinia
Street address
8th floor; -Fanavari Tarasht Tower; Teimori; Shahid Salehi Blvd
City
Tehran
Province
Tehran
Postal code
1459965204
Phone
+98 21 5461 2000
Email
info@dorsadarou.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Dorsa Pharmaceutical Co.
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Noor Research & Development Institute
Full name of responsible person
Behzad Montaha Sangari
Position
CEO(Chef Executive Officer)
Latest degree
Medical doctor
Other areas of specialty/work
Medical Pharmacy
Street address
Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht
City
Tehran
Province
Tehran
Postal code
1459926609
Phone
+98 21 6600 4027
Email
info@tavaninstitute.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tavan Institute
Full name of responsible person
Seyed Mohsen Foroutan
Position
Principal investigator
Latest degree

Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht.

City
Tehran

Province
Tehran

Postal code
1459926609

Phone
+98 21 6600 4027

Email
mforoutan@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Tavan Institute

Full name of responsible person
Behzad Montaha Sangari

Position
CEO(Chef executive officer)

Latest degree
Medical doctor

Other areas of specialty/work
Medical Pharmacy

Street address
Sharif innovation station, North Habibollah Street, Hosseini Square, Teymoury Street, Tarasht.

City
Tehran

Province
Tehran

Postal code
1459926609

Phone
+98 21 6600 4027

Email
info@tavaninstitute.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available

Study Protocol
No - There is not a plan to make this available

Statistical Analysis Plan
No - There is not a plan to make this available

Informed Consent Form
No - There is not a plan to make this available

Clinical Study Report
No - There is not a plan to make this available

Analytic Code
No - There is not a plan to make this available

Data Dictionary
No - There is not a plan to make this available